Eli Lilly granted partial approval for Alzheimer's medication

The FDA has concluded that Donanemab is effective for the treatment of Alzheimer’s in some patients in the early stages of the disease.
Photo: Mike Blake
Photo: Mike Blake
af marketwire

Eli Lilly’s potential Alzheimer’s drug, Donanemab, received a stamp of approval from a panel of US Food and Drug Administration experts on Monday, Bloomberg News reports. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading